Loading
RBX1 (E3 ubiquitin-protein ligase RBX1) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.
E3 ubiquitin ligase component of multiple cullin-RING-based E3 ubiquitin-protein ligase (CRLs) complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins, including proteins involved in cell cycle progression, signal transduction, transcription and transcription-coupled nucleotide excision repair. CRLs complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins, ARIH1 mediating addition of the first ubiquitin on CRLs targets. The functional specificity of the E3 ubiquitin-protein ligase complexes depends on the variable substrate recognition components.
Open Targets scores its association with cancer at 0.74 (direct and indirect evidence; datatypes literature 0.96, affected pathway 0.83, genetic association 0.03, clinical 0.99).
In plain words · RBX1 (E3 ubiquitin-protein ligase RBX1) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.
RBX1 (E3 ubiquitin-protein ligase RBX1) is an enzyme. The public catalogues list it as a drug target and a DNA repair gene, and an approved or late-stage drug is recorded against it. Tied to Multiple myeloma, Non-Hodgkin lymphoma, Myelodysplastic syndromes / neoplasms and 2 more.
E3 ubiquitin ligase component of multiple cullin-RING-based E3 ubiquitin-protein ligase (CRLs) complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins, including proteins involved in cell cycle progression, signal transduction, transcription and transcription-coupled nucleotide excision repair.
No product in this corpus aims at RBX1 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Broadly expressed or essential: HPA lists RBX1 among essential proteins and finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA RBX1: RNA low tissue specificity; no normal tissue stained high. Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Multiple myeloma, Lymphoma, Myeloid neoplasms); Open Targets associates it with 4 specific cancer types at or above 0.5 (plasma cell myeloma, follicular lymphoma, myelodysplastic syndrome, mantle cell lymphoma). (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas RBX1 tissue; Open Targets ENSG00000100387 associations
First described 1999. Earliest sequence paper UniProt cites for the protein: Ohta et al, Mol. Cell, 1999, "ROC1, a homolog of APC11, represents a family of cullin partners with an associated ubiquitin ligase activity". Source.
Sources: HGNC HGNC:9928 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P62877 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000100387 (association with cancer (MONDO_0004992) 0.74; per-cancer scores at or above 0.5: plasma cell myeloma 0.62, non-Hodgkin lymphoma 0.59, myelodysplastic syndrome 0.56, follicular lymphoma 0.57, mantle cell lymphoma 0.55 (GraphQL API, CC0))
E3 ubiquitin ligase component of multiple cullin-RING-based E3 ubiquitin-protein ligase (CRLs) complexes which mediate the ubiquitination and subsequent proteasomal degradation of target proteins, including proteins involved in cell cycle progression, signal transduction, transcription and transcription-coupled nucleotide excision repair. CRLs complexes and ARIH1 collaborate in tandem to mediate ubiquitination of target proteins, ARIH1 mediating addition of the first ubiquitin on CRLs targets. The functional specificity of the E3 ubiquitin-protein ligase complexes depends on the variable substrate recognition components. As a component of the CSA complex mediates ubiquitination of Pol II subunit POLR2A at 'Lys-1268', a critical TC-NER checkpoint. Core component of the Cul7-RING(FBXW8) ubiquitin ligase complex, which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Core component of a Cul9-RING ubiquitin ligase complex composed of CUL9 and RBX1, which mediates mono-ubiquitination of p53/TP53. Location: Cytoplasm; Nucleus (UniProt). Locus 22q13.2 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
HPA RBX1 tissue · HPA RBX1 pathology · HPA protein class: Essential proteins
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"RBX1" OR ABSTRACT:"RBX1" OR TITLE:"ring-box 1" OR ABSTRACT:"ring-box 1" OR TITLE:"E3 ubiquitin-protein ligase RBX1" OR ABSTRACT:"E3 ubiquitin-protein ligase RBX1" OR TITLE:"ROC1" OR ABSTRACT:"ROC1" OR TITLE:"RNF75" OR ABSTRACT:"RNF75" OR TITLE:"BA554C12.1" OR ABSTRACT:"BA554C12.1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RBX1, not a curated reading list.
Shares Myelodysplastic syndromes / neoplasms (MDS), Mantle cell lymphoma, Follicular lymphoma, Multiple myeloma.
Shares Myelodysplastic syndromes / neoplasms (MDS), Mantle cell lymphoma, Follicular lymphoma, Multiple myeloma.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.
Shares Myelodysplastic syndromes / neoplasms (MDS), Open Targets Platform.